InvestorsHub Logo
Followers 13
Posts 1320
Boards Moderated 0
Alias Born 12/30/2016

Re: Apophis post# 3247

Friday, 09/08/2017 3:43:18 PM

Friday, September 08, 2017 3:43:18 PM

Post# of 5907
Short Answer..... Nope! Next... Catalyst!

TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer
Phase 3
09/30/2017
Phase 3 completion of enrollment noted June 20, 2017. Futility analysis due September or early October, 2017. Noted early August that outcome is due in 1-2 months. Top-line data due 1Q 2018.





Go $AVEO